Hexarelin Peptide

Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) that exerts its primary biological effects through high-affinity agonism at two distinct receptor systems: the growth hormone secretagogue receptor type 1a (GHS-R1a) and the CD36 scavenger receptor. This dual receptor pharmacology distinguishes Hexarelin from purer GHS-R1a agonists such as Ipamorelin and underlies its unique profile in cardiovascular research models.

GHS-R1a Agonism and Growth Hormone Release

Hexarelin binds the GHS-R1a, a Gq-coupled seven-transmembrane receptor expressed predominantly in the pituitary and hypothalamus. Receptor activation triggers phospholipase C (PLC) stimulation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilises intracellular calcium and activates protein kinase C (PKC). The resulting calcium influx in pituitary somatotrophs drives exocytosis of growth hormone (GH) storage granules. In preclinical models, Hexarelin has demonstrated potency comparable to or exceeding GHRP-6, with sustained GH release observed at low microgram-per-kilogram doses [1].

Synergy with GHRH

Hexarelin acts at a receptor system distinct from the growth hormone-releasing hormone receptor (GHRH-R). Co-administration of Hexarelin with GHRH or GHRH analogues such as CJC-1295 produces additive or synergistic GH release in research models, attributed to complementary signaling through cAMP/PKA (GHRH-R) and PLC/IP3/Ca²⁺ (GHS-R1a) pathways. Hexarelin also functionally antagonises somatostatin tone, further amplifying GH pulse amplitude.

CD36 Receptor Binding

Unlike Ipamorelin, Hexarelin binds the CD36 scavenger receptor expressed on cardiomyocytes, macrophages, and vascular endothelial cells. CD36 engagement has been linked in preclinical literature to modulation of cardiac contractility, coronary perfusion, and lipid handling pathways independent of GH release [2]. This off-target receptor interaction underlies the cardiovascular research interest in Hexarelin.

Downstream Endocrine Effects

GH release from somatotrophs stimulates hepatic insulin-like growth factor 1 (IGF-1) production via JAK2/STAT5 signaling. Elevated IGF-1 mediates many anabolic effects observed in GH research, including protein synthesis stimulation and modulation of cellular proliferation pathways. Hexarelin has also been reported to induce modest, transient increases in cortisol and prolactin in some preclinical models, although these effects are typically smaller than those of GHRP-6.

Receptor Desensitisation

Chronic Hexarelin administration in preclinical models has been associated with attenuation of subsequent GH responses, attributed to GHS-R1a desensitisation through β-arrestin recruitment and receptor internalisation. This pharmacodynamic feature is relevant to research dosing protocols and distinguishes secretagogue pharmacology from direct exogenous GH administration.

The following table summarises the verified chemical and physical properties of Hexarelin as referenced from PubChem and primary pharmacological literature.

The N-methylation of tryptophan and incorporation of D-amino acids at positions 2 and 5 confer marked resistance to enzymatic degradation by peptidases relative to the parent GHRP-6 scaffold, extending plasma half-life and enabling oral and intranasal bioavailability. The C-terminal lysine amide is essential for GHS-R1a binding affinity, while the D-2-methyl-Trp substitution increases receptor selectivity and potency. Hexarelin's compact six-residue structure and stability profile make it a frequently used reference compound in GHS pharmacology research.

Hexarelin is supplied as a sterile lyophilized powder and requires reconstitution with an appropriate sterile diluent before use in laboratory research applications. Proper handling preserves peptide integrity and ensures consistent dosing for in vitro and preclinical research protocols.

Recommended Reconstitution Protocol

1. Allow the vial to equilibrate to room temperature for 15-20 minutes after removal from cold storage. This prevents condensation from forming inside the vial upon opening.
2. Select an appropriate diluent. Bacteriostatic water (0.9% benzyl alcohol) is the standard choice for multi-use research vials. Sterile water for injection or 0.9% sodium chloride may also be used for single-session protocols.
3. Calculate the target concentration. For a 5 mg vial reconstituted with 2 mL of diluent, the resulting concentration is 2.5 mg/mL (2,500 mcg/mL). For 1 mL diluent, the concentration is 5 mg/mL.
4. Inject the diluent slowly down the inner wall of the vial. Do not aim the stream directly at the lyophilized powder, as the force can damage peptide structure.
5. Swirl gently with a circular wrist motion until the powder fully dissolves. Do not shake or vortex — agitation can shear the peptide backbone and reduce activity.
6. Inspect visually. The reconstituted solution should be clear and colorless, with no visible particulates or cloudiness.
7. Label the vial with reconstitution date, diluent used, and resulting concentration.

Compound-Specific Notes

Hexarelin contains a tryptophan residue and a D-2-methyl-tryptophan modification, both of which are sensitive to UV light and oxidation. Store reconstituted vials in amber containers or wrap in foil when possible. Avoid repeated freeze-thaw cycles of the reconstituted solution. For long-term storage of stock solutions, consider aliquoting into single-use volumes to minimize repeated vial entry.

Use sterile, low-binding pipette tips when transferring solutions for assay work, as peptides can adsorb to standard polypropylene surfaces at low concentrations, reducing effective dose. For dilutions below 100 mcg/mL, the addition of carrier protein (e.g., 0.1% BSA) to working buffers is commonly used in receptor binding studies.

Proper storage is essential to maintain Hexarelin potency and purity throughout research use. The peptide is chemically stable in its lyophilized form but becomes more susceptible to degradation once reconstituted into aqueous solution.

Lyophilized Powder Storage

• Long-term storage: Store sealed vials at -20°C or colder. Under these conditions, lyophilized Hexarelin retains documented stability for 24 months or longer when protected from light and moisture.
• Short-term storage: Refrigeration at 2-8°C is acceptable for periods up to 30-60 days if frequent access is required.
• Transit / room temperature: Lyophilized Hexarelin tolerates ambient temperatures (up to ~25°C) for shipping periods of 1-2 weeks without significant loss of activity, owing to the stability of the dry powder form.

Reconstituted Solution Storage

• Store reconstituted Hexarelin at 2-8°C (standard laboratory refrigeration).
• When prepared with bacteriostatic water, reconstituted vials are generally stable for up to 28 days at refrigerated temperatures, consistent with the preservative action of benzyl alcohol.
• Solutions prepared with non-bacteriostatic diluent (sterile water, saline) should be used within 7-10 days or aliquoted and frozen at -20°C for longer storage.

Compound-Specific Stability Notes

Hexarelin contains two indole-bearing residues (Trp and D-2-MeTrp) that are vulnerable to photooxidation. Protect both lyophilized vials and reconstituted solutions from direct light. The peptide does not contain disulfide bonds, so it is not susceptible to reduction-mediated degradation, but it does carry a free N-terminus and C-terminal amide that should be considered when designing buffer systems. Avoid storage in alkaline buffers (pH > 8.0) for extended periods, as this can accelerate hydrolysis of the amide bond at the C-terminus. Repeated freeze-thaw cycles should be minimized; researchers typically aliquot stock solutions into single-use volumes prior to freezing.